Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
about
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated PneumoniaMethicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyLinezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.Benefit-risk assessment of linezolid for serious gram-positive bacterial infections.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.MRSA: treating people with infection.Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study.Novel streptogramin antibiotics.Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment.Critical care medicine in AJRCCM 2000.Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.Guidelines on antimicrobial chemotherapy for prevention and treatment of infections in the intensive care unit.Cutaneous infections in the elderly: diagnosis and management.New therapeutic agents for resistant Gram-positive infections.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists.Nosocomial bacterial infections in Intensive Care Units. I: Organisms and mechanisms of antibiotic resistance.Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection.Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.Gram-positive cocci infections in intensive care: guide to antibacterial selection.Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.New antimicrobial agents as therapy for resistant gram-positive cocci.Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Newer developments in the treatment of Gram-positive infections.Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia.Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.Is linezolid superior to vancomycin for complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus?Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designUse of intravenous co-trimoxazole to treat bacterial infection: analysis of 50 treatment episodes.Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus.Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis.MRSA (treatment).Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?Acute Onset of Pneumococcal Pneumonia Following Instrumentation of the Respiratory Tract.
P2860
Q22241905-A5A18B5F-F1BE-4BCD-BC4C-6E4EC0961720Q28235095-CBEA15AF-646E-42B3-A2CE-209D62F6EDBAQ31918107-FEF8135D-7B25-4D66-B689-68C9AAF5C856Q33380788-4D97CE7D-3F00-45F6-8A66-C07A483D004FQ33617737-3BBDF2CB-FAF9-49AB-A85F-925ED789A08AQ33657212-8ED1042B-4B82-4711-885F-FE8B7FC811B5Q33850476-8C09E68B-0FF9-4130-AC15-B9056D933C05Q34117775-E561B40C-1294-4BB5-BBFF-765134399540Q34141055-8D214AE0-3507-4D85-B09C-AD1E87D8B8DBQ34404666-2E3E85F8-B12C-4AE2-BAE4-BB1D485EB077Q34435267-68805C0D-29BA-4ACA-BF51-850F46F9555EQ34470298-4595C3E6-97A7-406B-9911-A9F41C0F0050Q34589960-48C6BCF1-133B-47F4-929E-BF5B2500F82CQ35544159-40E6AD1D-AF38-4C60-A44A-7BD25A3445F7Q35917308-A0584BB7-1E08-4F98-93A0-E6CA2A1F5B08Q36078359-BA2D1A11-8CD0-4BCC-A9E5-C22F7AD71693Q36188333-5069089F-A2F7-46AB-B4FF-7982B96E49D5Q36237707-BE1257A0-F572-431F-85C9-B4FCDEC7C926Q36338182-5A45B3AB-C56E-4B67-83BA-24EC3EF2A2D1Q36409465-F6A350A0-B51E-4637-8831-B781D4E5F9D0Q36480958-2335BF9B-9BB3-4F1E-A3AE-BBA75C623ABDQ36735202-C6D7C5EC-177A-4F68-9B23-BC03B3F41C1BQ36758570-B6DF2653-A994-43AC-AC58-29946C06266DQ36953330-2DCCCA7C-A6AB-41AB-97DF-DBF4BDD67E80Q37029217-31E9F942-05F7-4F72-B174-586C14B2A77CQ37563029-55DAB7E2-3E52-4994-BB4A-BF446DCAAF69Q37636151-B57BC7A4-C03C-47D1-8ABC-B578849162C0Q37821604-6129CB95-525B-4FD9-940F-50D11D6C7B1EQ37992997-B4F0D225-6C4D-4128-9165-A327FC9B9C9FQ38066654-D40E630C-0843-4603-A63E-2E4241E0DEADQ38907793-B9CA6940-50F4-4B95-911E-D101690CE860Q40667218-AA2E03B7-EA27-45FA-BC1D-2C7EF7949C41Q42424814-FCC71ED1-BC3B-4029-916A-B37988C458D5Q42544277-08BBFD1D-1631-49E2-9FD7-AEA0112B4C93Q42946333-FD6A1FCD-AF31-4030-8202-DE9C1201E66EQ44313451-41800899-C856-4797-ACA8-768D7C4CC3C3Q44808648-36426EE7-2B39-4C67-87F4-E3F366D04BD4Q46012005-DD2EF8BE-C9A6-41EF-A46F-668C5EC1665AQ46728126-A399AF7D-1715-4466-95F8-DE0FA2714730Q53830743-4DB64C06-424F-4545-B3C0-2C5997BB1EA4
P2860
Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Treatment of gram-positive nos ...... n. Nosocomial Pneumonia Group.
@en
Treatment of gram-positive nos ...... n. Nosocomial Pneumonia Group.
@nl
type
label
Treatment of gram-positive nos ...... n. Nosocomial Pneumonia Group.
@en
Treatment of gram-positive nos ...... n. Nosocomial Pneumonia Group.
@nl
prefLabel
Treatment of gram-positive nos ...... n. Nosocomial Pneumonia Group.
@en
Treatment of gram-positive nos ...... n. Nosocomial Pneumonia Group.
@nl
P2093
P2860
P1476
Treatment of gram-positive nos ...... n. Nosocomial Pneumonia Group.
@en
P2093
Cheadle WG
Falcone RE
Lilienthal F
P2860
P304
P356
10.1164/AJRCCM.161.3.9904115
P407
P433
P577
2000-03-01T00:00:00Z